Fig. 1 · Structure

Documents & Downloads

Atopaxar hydrobromide

Cat. No. A13813 CAS 474550-69-1
Atopaxar hydrobromide shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC values of 0.064 and 0.031 μM respectively.

In Stock

Publications for Atopaxar hydrobromide

1 publication citing this product

  1. Lehmann M, .et al. , Arterioscler Thromb Vasc Biol, 2018, May;38(5):1052-1062 PMID: 29472230

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Atopaxar hydrobromide Research Summary

This section summarizes 4 in vitro studies of Atopaxar hydrobromide from 3 published references. In vitro models include cultured intestinal myofibroblasts; E4+ HUVEC.

Atopaxar hydrobromide In Vitro Studies

In cultured intestinal myofibroblasts, Atopaxar pretreatment inhibited ERK1/2 phosphorylation in the comparison with thrombin control. Atopaxar hydrobromide added to iCell neuron media was not significantly more toxic than control media containing the same DMSO concentration. In E4+ HUVEC, Atopaxar pretreatment abolished the E-selectin expression response to TFLLR. In cultured intestinal myofibroblasts, Atopaxar prevented IL6-induced, but not basal, phosphorylation of STAT3. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Atopaxar inhibits thrombin-induced ERK1/2 phosphorylation

Cell-based study · cultured intestinal myofibroblasts [1]

In cultured intestinal myofibroblasts, Atopaxar pretreatment inhibited ERK1/2 phosphorylation compared with thrombin treatment alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phosphorylation of ERK1/2Reported result The ERK1/2 phosphorylation was inhibited by pretreatment with 1 μmol/L E5555[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μmol/L
Exposure duration
thrombin for 5 minutes
Method
pretreatment
Co-treatment
Other interventions in this design: thrombin 1 U/mL. Compound effect isolated by the comparison: 1 U/mL thrombin.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Atopaxar; Compound label in the paper: E5555

The paper names Atopaxar without stating the salt or form; not verified as the hydrobromide form supplied as A13813. No dose conversion or lot validation.

Results > E5555 Suppressed the Phosphorylation of ERK and STAT3 in the Cultured Intestinal Myofibroblasts (S87, S88, S91)

phosphorylation of ERK1/2: phosphorylation of ERK1/2; comparator: 1 U/mL thrombin — Results > E5555 Suppressed the Phosphorylation of ERK and STAT3 in the Cultured Intestinal Myofibroblasts (S88, S91)

Atopaxar neuronal toxicity assessment

Cell-based study · iCell neurons; n = 8 per condition [2]

In iCell neurons, Atopaxar hydrobromide was placed into the media. Treatment was not significantly more toxic than control media containing the same concentration of DMSO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
toxicityReported result nor was Atopaxar itself significantly more toxic than control media[2]

Literature-Reported Treatment Conditions

Method
placed into the media
Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose, schedule.
Methods and source locations

Compound reported in the paper: Atopaxar hydrobromide; Compound label in the paper: Atopaxar

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Neuronal cultures (S6); Results > PAR1 activation mediates granzyme B neurotoxicity (S144); Fig. 6 legend (S194)

toxicity: toxicity; comparator: control media, which contained the same concentration of DMSO necessary to solubilize Atopaxar — Fig. 6 legend (S194)

Atopaxar and endothelial E-selectin expression

Cell-based study · E4+ HUVEC [3]

In E4+ HUVEC, Atopaxar pretreatment abolished the E-selectin expression response to the agonist peptide TFLLR.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
E-selectin expressionReported result Pretreatment of endothelial cells with a PAR-1 antagonist, E5555, abolished the responses to the PAR-1 agonist peptide.[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 μM
Exposure duration
for 30 min at 37°C
Method
Pretreatment of endothelial cells
Co-treatment
Other interventions in this design: TFLLR 100 μM; amastatin 10 μM. Compound effect isolated by the comparison: PAR-1 agonist peptide, TFLLR.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Atopaxar; Compound label in the paper: E5555

The paper names Atopaxar without stating the salt or form; not verified as the hydrobromide form supplied as A13813. No dose conversion or lot validation.

Materials and Methods > Exposure of Endothelial Cells to EV (S26, S27); Results > TF-Expressing Tumor-Derived EV Upregulate Endothelial E-Selectin Expression and Induce IL-8 Secretion in a TF-, FXa-, and PAR-1-Dependent, but PAR-2-Independent, Manner (S80, S82); Figure 5 legend (S117, S119)

E-selectin expression: E-selectin expression; comparator: PAR-1 agonist peptide, TFLLR — Results > TF-Expressing Tumor-Derived EV Upregulate Endothelial E-Selectin Expression and Induce IL-8 Secretion in a TF-, FXa-, and PAR-1-Dependent, but PAR-2-Independent, Manner (S82); Figure 5 legend (S119)

Atopaxar prevents IL6-induced STAT3 phosphorylation

Cell-based study · cultured intestinal myofibroblasts [1]

In cultured intestinal myofibroblasts, Atopaxar prevented IL6-induced STAT3 phosphorylation compared with IL6 treatment alone, while basal STAT3 phosphorylation was unaffected.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phosphorylation of STAT3Reported result 1 μmol/L E5555 prevented the IL6-induced, but not basal, phosphorylation of STAT3[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μmol/L
Co-treatment
Other interventions in this design: IL6 5 ng/mL. Compound effect isolated by the comparison: 5 ng/mL IL6.
Reported limits
Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Atopaxar; Compound label in the paper: E5555

The paper names Atopaxar without stating the salt or form; not verified as the hydrobromide form supplied as A13813. No dose conversion or lot validation.

Results > E5555 Suppressed the Phosphorylation of ERK and STAT3 in the Cultured Intestinal Myofibroblasts (S90, S93)

phosphorylation of STAT3: phosphorylation of STAT3; comparator: 5 ng/mL IL6 — Results > E5555 Suppressed the Phosphorylation of ERK and STAT3 in the Cultured Intestinal Myofibroblasts (S90, S93)

Specifications

Manufacturer Adooq Bioscience
CAS Number 474550-69-1
Formula C29H39BrFN3O5
Molecular Weight 608.54
Synonyms ER172594-06; E5555
SMILES
CCOC1=C(C(=C2C(=C1)CN(C2=N)CC(=O)C3=CC(=C(C(=C3)N4CCOCC4)OC)C(C)(C)C)F)OCC.Br

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Atopaxar hydrobromide Research References

  1. [1] Li X, Kurahara LH, Zhao Z, et al. Therapeutic Effect of Proteinase-Activated Receptor-1 Antagonist on Colitis-Associated Carcinogenesis. Cell Mol Gastroenterol Hepatol (2024). PMID: 38614455 DOI: 10.1016/j.jcmgh.2024.04.001 Source material
  2. [2] Lee PR, Johnson TP, Gnanapavan S, et al. Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β. J Neuroinflammation (2017). PMID: 28655310 DOI: 10.1186/s12974-017-0901-y Source material
  3. [3] Che SPY, Park JY, Stokol T. Tissue Factor-Expressing Tumor-Derived Extracellular Vesicles Activate Quiescent Endothelial Cells via Protease-Activated Receptor-1. Front Oncol (2017). PMID: 29164060 DOI: 10.3389/fonc.2017.00261 Source material

Publications

1 publication citing this product

  1. Lehmann M, .et al. , Arterioscler Thromb Vasc Biol, 2018, May;38(5):1052-1062 PMID: 29472230

Added to your cart

View Cart Checkout
Loading...